On 27 October 2026 the Indian Patent Office rejected the patent application of the US-based non-profit TB Alliance (Global Alliance for TB Drug Development) for BPaL — bedaquiline, pretomanid and linezolid — a six-month, all-oral regimen for drug-resistant TB.
The application, filed on 16 April 2018, faced pre-grant oppositions under Section 25(1) of the Patents Act, 1970, filed in July 2020 by civil society groups including the Delhi Network of Positive People and Sankalp Rehabilitation Trust.
The office found lack of novelty and inventive step, non-patentability and insufficient disclosure, invoking Sections 3(d), 3(e) and 3(i); opponents showed the combination and its shorter regimen were disclosed in research and trials from 2015.
India had an estimated 2.71 million new TB cases in 2024, about a quarter of the world's; more than 15,000 patients have received the related BPaLM regimen (BPaL plus moxifloxacin) under NTEP.
The order covers only this Indian application; TB Alliance holds 11 BPaL-related patents abroad, including in Armenia, Azerbaijan and South Africa, expiring in 2036.
Any person may oppose an application after it is published and before a patent is granted; the BPaL oppositions were filed under it in July 2020.
Bars patents on a new form of a known substance unless it shows enhanced efficacy; the Supreme Court upheld it in Novartis v Union of India (2013, the Glivec/imatinib case).
Excludes a mere admixture of known substances that only aggregates their properties — the core objection to a combination of three known drugs.
Excludes methods of medical treatment of human beings, so a dosing regimen as such cannot be patented.
Abolished the Intellectual Property Appellate Board; appeals against the Controller's orders now go to the High Court.
Examines patent applications and decides oppositions
US-based non-profit drug developer; developed pretomanid and filed the BPaL application
Drug regulator; had approved and licensed pretomanid for use in India before BPaLM's rollout
Eliminate TB in India; renamed from the Revised National TB Control Programme (RNTCP) in 2020
Key: Approved the six-month BPaLM regimen for drug-resistant TB in September 2024, replacing regimens of up to 20 months
Research and clinical trials disclose the three-drug combination and its shorter regimen (cited as prior art)
TB Alliance files the BPaL patent application in India
Civil society groups file pre-grant oppositions under Section 25(1)
Union Health Ministry approves the BPaLM regimen for NTEP
Indian Patent Office rejects the application
GS Paper 3 > Science and Technology > Intellectual Property Rights
GS Paper 2 > Health > Communicable diseases and access to medicines
General Awareness > Science > Diseases and drugs
A challenge any person can file after an application is published and before the patent is granted — Section 25(1)
Extending patent protection through minor changes to a known drug; Section 3(d) is India's main safeguard against it
A feature that is not obvious to a person skilled in the art; its absence was one ground here
Bedaquiline, pretomanid, linezolid and moxifloxacin — the six-month regimen used under NTEP since 2024